Plain-English translation of NCT06674694 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 trial testing , a new medication designed to treat schizophrenia. Researchers are studying whether this medication is safe and well-tolerated when given as a single injection. The study will include both healthy volunteers and people who have been diagnosed with schizophrenia.
Currently available schizophrenia medications often require frequent doses, which can make it hard for patients to stay consistent with treatment. This medication is designed as a long-acting injection, meaning it could work longer in the body with just one dose—making treatment simpler and potentially more effective.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive a single injection of the study medication at one dose level. Healthy volunteers will start with the lowest dose (20 mg), while people with schizophrenia may be in higher-dose groups depending on the results from earlier groups. You will have blood tests, physical exams, and heart tracings done before and after the injection to monitor how your body responds to the medication. The study will track your safety and how the medication moves through your body over time.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
China